Alpha 2.0
Login Register
» Articles » PMID: 33890566

Characteristics of SARS-CoV-2 Variants of Concern B.1.1.7, B.1.351 or P.1: Data from Seven EU/EEA Countries, Weeks 38/2020 to 10/2021

Overview
Journal Euro Surveill
Specialty Infectious Diseases
Date 2021 Apr 23
PMID 33890566
Citations 173
Authors
Tjede Funk
Anastasia Pharris
Gianfranco Spiteri
Nick Bundle
Angeliki Melidou
Michael Carr
Gabriel Gonzalez
Alejandro Garcia-Leon
Fiona Crispie
Lois OConnor
Niamh Murphy
Joel Mossong
Anne Vergison
Anke K Wienecke-Baldacchino
Tamir Abdelrahman
Flavia Riccardo
Paola Stefanelli
Angela Di Martino
Antonino Bella
Alessandra Lo Presti
Pedro Casaca
Joana Moreno
Vitor Borges
Joana Isidro
Rita Ferreira
Joao Paulo Gomes
Liidia Dotsenko
Heleene Suija
Jevgenia Epstein
Olga Sadikova
Hanna Sepp
Niina Ikonen
Carita Savolainen-Kopra
Soile Blomqvist
Teemu Mottonen
Otto Helve
Joana Gomes-Dias
Cornelia Adlhoch
Affiliations
Soon will be listed here.
Abstract

We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95% CI: 2.1-6.2; P.1: 2.6, 95% CI: 1.4-4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4-3.5; P.1: 2.2, 95% CI: 1.7-2.8).

Citing Articles

Structural proteins of human coronaviruses: what makes them different?.

Minigulov N, Boranbayev K, Bekbossynova A, Gadilgereyeva B, Filchakova O Front Cell Infect Microbiol. 2024; 14:1458383.

PMID: 39711780 PMC: 11659265. DOI: 10.3389/fcimb.2024.1458383.

Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies.

Barghash R, Gemmati D, Awad A, Elbakry M, Tisato V, Awad K Molecules. 2024; 29(23.

PMID: 39683724 PMC: 11643501. DOI: 10.3390/molecules29235564.

Planning and adjusting the COVID-19 booster vaccination campaign to reduce disease burden.

Di Domenico L, Goldberg Y, Colizza V Infect Dis Model. 2024; 10(1):150-162.

PMID: 39380724 PMC: 11459620. DOI: 10.1016/j.idm.2024.09.002.

The Clinical Severity of COVID-19 Variants of Concern: Retrospective Population-Based Analysis.

Harrigan S, Velasquez Garcia H, Abdia Y, Wilton J, Prystajecky N, Tyson J JMIR Public Health Surveill. 2024; 10():e45513.

PMID: 39190434 PMC: 11387920. DOI: 10.2196/45513.

Focus, vigilance, resilience: towards stronger infectious disease surveillance, threat detection and response in the EU/EEA.

Zucs P, Beaute J, Palm D, Spiteri G Euro Surveill. 2024; 29(34).

PMID: 39176987 PMC: 11367071. DOI: 10.2807/1560-7917.ES.2024.29.34.2400066.

References
1.
Borges V, Sousa C, Menezes L, Goncalves A, Picao M, Almeida J . Tracking SARS-CoV-2 lineage B.1.1.7 dissemination: insights from nationwide spike gene target failure (SGTF) and spike gene late detection (SGTL) data, Portugal, week 49 2020 to week 3 2021. Euro Surveill. 2021; 26(10). PMC: 7953529. DOI: 10.2807/1560-7917.ES.2021.26.10.2100130. View
2.
Challen R, Brooks-Pollock E, Read J, Dyson L, Tsaneva-Atanasova K, Danon L . Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021; 372:n579. PMC: 7941603. DOI: 10.1136/bmj.n579. View
3.
Davies N, Jarvis C, Edmunds W, Jewell N, Diaz-Ordaz K, Keogh R . Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021; 593(7858):270-274. PMC: 9170116. DOI: 10.1038/s41586-021-03426-1. View
4.
Bager P, Wohlfahrt J, Fonager J, Rasmussen M, Albertsen M, Michaelsen T . Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. Lancet Infect Dis. 2021; 21(11):1507-1517. PMC: 8219488. DOI: 10.1016/S1473-3099(21)00290-5. View
5.
Madhi S, Baillie V, Cutland C, Voysey M, Koen A, Fairlie L . Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021; 384(20):1885-1898. PMC: 7993410. DOI: 10.1056/NEJMoa2102214. View